Jane Street’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Jane Street’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27,892	Closed	-$121K	–	9685
2020 Q4	$121K	Buy	+27,892	New	+$131K	﹤0.01%	7150

Other funds holding CYTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Jane Street's CYTH Position: Q1 2021 in Review

Jane Street sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2021, closing a stake of 27,892 shares — an estimated $121K sold.

Jane Street first reported a position in CYTH in Q4 2020 and held it in 1 quarter. The position peaked at $121K in Q4 2020. 9 funds tracked by Wall St. Rank hold CYTH as of Q1 2021.

Jane Street reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Jane Street sold 27,892 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $121K.
Jane Street first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Jane Street's Cyclo Therapeutics, Inc. Common Stock position peaked at $121K in Q4 2020.
9 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Jane Street's 13F filing for Q1 2021, filed 18 May 2021.